Physician profile
Angelo Mallozzi
NPI 1871053850
$1,436.94
in general payments reported to CMS, 2019-2025
12 companies · $367 in 2025
The $367 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $421 · 2024: $649 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,436.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $298.29 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $261.30 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $238.07 | 2023-2024 | Spravato |
| Neurocrine Biosciences, INC. | $165.24 | 2024-2025 | Ingrezza |
| Si-Bone, INC. | $143.31 | 2023 | |
| Vanda Pharmaceuticals INC. | $91.89 | 2024 | Fanapt, Hetlioz |
| Lundbeck LLC | $85.64 | 2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $46.95 | 2023-2024 | Qelbree, Qelbree |
| Neos Therapeutics, LP | $38.46 | 2024 | Adzenys Xr-Odt |
| Biogen, INC. | $29.37 | 2024 | |
| Idorsia Pharmaceuticals US INC | $22.73 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $15.69 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angelo Mallozzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.